Atrium Therapeutics, Inc. (RNA) Stock

NASDAQ: RNAHealthcare company in the biotechnology industry, based in San Diego, CA.

Atrium Therapeutics stock price chart

RNA stock quote & key statistics

Atrium Therapeutics earnings per share

Earnings per share

Atrium Therapeutics revenue & net income

RevenueNet income

Atrium Therapeutics annual financials

Fiscal yearRevenueNet incomeEPS
FY2025$18.6M-$76.7M-$4.97
FY2024$10.9M-$322.3M-$2.89
FY2023$9.6M-$212.2M-$2.90
FY2022$9.2M-$169.1M-$3.33
FY2021$9.3M-$117.4M-$2.84

Fiscal year ending December 31. Source: company filings via EODHD.

About Atrium Therapeutics, Inc.

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy.

It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California.

Atrium Therapeutics stock FAQ

What is the Atrium Therapeutics stock ticker symbol?

Atrium Therapeutics, Inc. trades on the NASDAQ under the ticker symbol RNA.

What sector and industry is Atrium Therapeutics in?

Atrium Therapeutics, Inc. is classified in the Healthcare sector, Biotechnology industry.

How many employees does Atrium Therapeutics have?

Atrium Therapeutics, Inc. has about 511 full-time employees.

What were Atrium Therapeutics's revenue and earnings last fiscal year?

Atrium Therapeutics reported revenue of $18.6M and net income of -$76.7M in fiscal 2025, with earnings per share of -$4.97. Revenue grew 70.9% from the prior year.

Is Atrium Therapeutics in the Russell 2000?

Yes. Atrium Therapeutics, Inc. (RNA) is a component of the Russell 2000, the benchmark index of U.S. small-cap stocks.

When did Atrium Therapeutics go public?

Atrium Therapeutics stock began trading on June 28, 2013.

Russell 2000 Biotechnology stocks

All Russell 2000 →